Corrigendum to "the IL-6 Hypothesis in COVID-19: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Free IL-6 Sequestration by the Monoclonal Antibody Sirukumab in Severe and Critical COVID-19" [J Infect 89 (2024) 106241].
Journal of Infection（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined